SECRENNING for ELIGIBILITY
Renal Transplant recipients >1 year post-transplantation (n ≈ 4672)
CONSENT
n ≈ 2,522

BLOOD TEST
Screening for HLA Ab

HIGH RISK
HLA Ab + group

Single Antigen Bead Analysis
(Determine DSA present)

DSA
1/3
Non-DSA
2/3

Treatment Randomisation (1:1)*
(Stratified by baseline Tac. and MMF)

A1: Blinded Standard Care N=139€
B1: Unblinded Biomarker-led Care N=139€
A2: Blinded Standard Care N=278€
B2: Unblinded Biomarker-led Care N=278€

Screening Results:
Double Blind Treatment:
Remain on baseline immunotherapy unless clinical indication to change.

Screening Results:
Unblinded Treatment:
Optimised immunosuppression
Medication optimisation protocol implemented
Course of prednisolone, and conversion to or optimisation of tacrolimus and MMF

Screening Results:
Unblinded Treatment:
Optimised immunosuppression
Medication optimisation protocol implemented
Course of prednisolone, and conversion to or optimisation of tacrolimus and MMF

Screening Results:
Unblinded to screening results Treatment:
Remain on baseline immunotherapy unless clinical indication to change.

Screening rounds 2-5†